BCM
XERS icon

Bridgeway Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Bridgeway Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,100
Closed -$33.1K – 1381
2023
Q4 		$33.1K Hold
14,100
– – ﹤0.01% 1332
2023
Q3 		$26.2K Sell
14,100
-250,351
-95% -$574K ﹤0.01% 1334
2023
Q2 		$693K Hold
264,451
– – 0.02% 818
2023
Q1 		$431K Sell
264,451
-100,000
-27% -$125K 0.01% 921
2022
Q4 		$485K Buy
364,451
+70,000
+24% +$98.8K 0.01% 887
2022
Q3 		$459K Buy
294,451
+151,800
+106% +$251K 0.01% 914
2022
Q2 		$220K Hold
142,651
– – 0.01% 1074
2022
Q1 		$365K Sell
142,651
-99,500
-41% -$243K 0.01% 1017
2021
Q4 		$710K Sell
242,151
-160,149
-40% -$346K 0.01% 877
2021
Q3 		$986K Buy
402,300
+174,300
+76% +$506K 0.02% 836
2021
Q2 		$928K Sell
228,000
-30,000
-12% -$114K 0.02% 885
2021
Q1 		$1.16M Buy
258,000
+109,000
+73% +$588K 0.02% 805
2020
Q4 		$733K Sell
149,000
-69,000
-32% -$345K 0.02% 827
2020
Q3 		$1.29M Hold
218,000
– – 0.03% 584
2020
Q2 		$580K Buy
218,000
+100,000
+85% +$348K 0.01% 808
2020
Q1 		$230K Buy
+118,000
New +$507K 0.01% 1014

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

Bridgeway Capital Management's XERS Position: Q1 2024 in Review

Bridgeway Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q1 2024, closing a stake of 14,100 shares — an estimated $33.1K sold.

Bridgeway Capital Management first reported a position in XERS in Q1 2020 and held it in 16 quarters. The position peaked at $1.29M in Q3 2020. 143 funds tracked by Wall St. Rank hold XERS as of Q1 2024.

  • Bridgeway Capital Management reported no remaining Xeris Biopharma Holdings position as of Q1 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 14,100 Xeris Biopharma Holdings shares in Q1 2024, an estimated $33.1K.
  • Bridgeway Capital Management first reported a position in Xeris Biopharma Holdings in Q1 2020 and held it in 16 quarters.
  • Bridgeway Capital Management's Xeris Biopharma Holdings position peaked at $1.29M in Q3 2020.
  • 143 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2024.

Based on Bridgeway Capital Management's 13F filing for Q1 2024, filed 15 May 2024.